Changes in Hong Kong stocks | Kaituo Pharmaceutical-B (09939) rose more than 12% KX-826 long-term safety test for hair loss completed and will be submitted to the State Drug Administration

The Zhitong Finance App learned that the stock price of Kaituo Pharmaceutical-B (09939) rose by 12.70% as of press release to HK$1.42, with a turnover of HK$523,300.

According to the news, Kaituo Pharmaceutical announced this morning that its self-developed long-term safety clinical trial of 1.0% KX-826 tincture to treat androgen alopecia (AGA) has been followed up with all subjects, showing good safety.

As a necessary test for KX-826 to submit a New Drug Marketing Application (NDA), the results of this long-term safety clinical trial further confirm the safety and efficacy of the long-term use of KX-826. The above results will be included in the main NDA reporting materials along with materials such as the positive results of the phase III clinical trial announced in March 2026, and will be submitted to the National Drug Administration in the near future.